Syndax Pharmaceuticals, Inc. (SNDX Quick QuoteSNDX - Free Report) was a big mover last session, as the company saw its shares rise over 14% on the day. The upside was driven after the company announced entering into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). The news also led to far more shares changing hands than in a normal session, resulting in solid volume. This reverses the recent trend of the company, as the stock is now down 14.8% since Dec 7.

None of the estimates for this stock were revised over the last 30 days, while the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Syndax Pharmaceuticals carries a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked stock in the same industry is Arbutus Biopharma Corporation (ABUS Quick QuoteABUS - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is SNDX going up? Or down? Predict to see what others think: Up or Down

The Best Place to Start Your Stock Search

Today, you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>